Xuchang Ketop Testing Research Ins (003008) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Xuchang Ketop Testing Research Ins stock ¥15.53, price ¥17.56, that is 11.6% below the price, quality 74 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range ¥10.33 – ¥26.33 · fair‑value band ¥10.58 – ¥20.93 · the ¥17.56 price screens above the ¥15.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Xuchang Ketop Testing Research Ins in your weekly email
Every Wednesday you see whether Xuchang Ketop Testing Research Ins is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Xuchang KETOP Testing Research Institute Co.,Ltd operates as a third-party testing company in China.
Show moreShow less
It provides testing services for protection and control equipment, charging and swapping equipment, AC/DC power supply equipment testing, new energy photovoltaic energy storage converter transformer equipment, distribution network terminal equipment, electromagnetic compatibility, environmental and reliability testing, plant simulation modeling testing, software and cybersecurity testing, on-site acceptance testing, testing of monitoring system equipment, online monitoring equipment testing, other types of equipment testing, medical electrical equipment testing, automotive electronic equipment testing, remote sensing equipment testing, intelligent transportation equipment testing, and testing of household appliances.
The company was founded in 2005 and is based in Xuchang, China.
Stock analysis
Xuchang Ketop Testing Research Ins (003008) currently trades at ¥17.56, while our model-based Fair Value estimate is ¥15.53, 12% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥18.02 per share, and 7 of the 26 models we run sit above the ¥17.56 price.
Bear case: the Asset-Based group reads lowest at ¥6.46, and 19 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥10.58 (bear) to ¥20.93 (bull), the price of ¥17.56 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Industrials sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Xuchang Ketop Testing Research Ins reported revenue of 233M CNY in FY2025 versus 144M CNY in FY2021, a compound +12.8%/yr. Reported net income was 88.2M CNY in FY2025, compounding +8.2%/yr from FY2021.
Key figures
Market cap 1.8B CNY (≈ $273M) Micro · P/E ratio 22.2 · P/S ratio 8.22 · EPS (TTM) ¥0.7900 · Dividend yield 2.8% · Net margin 36.9% · Return on equity 7.9% · Return on assets (EBIT) 7.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −12% fair-value upside, at −12%, 003008 screens cheaper than that median.
Fair Value models
Bear¥10.58Fair Value ¥15.53Bull¥20.93
Price ¥17.56 · Downside -11.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.2487 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+2.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.6%
Dividend (yield on the price)2.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.6% vs −9.4%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.50% → 46%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 2.0%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +3.2% a year for the price.
Compare Xuchang Ketop Testing Research Ins with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Business Services · 231 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside−11.6% · Below median
Profitability
Return on equity (12 months)7.9% · Below median
Return on assets7.9% · Above median
Net margin (12 months)36.9% · Top 25%
Operating margin (12 months)35.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)8.1% · Above median
Dividend yield (12 months)2.8% · Below median
Valuation Multiplesvs Specialty Business Services median · lower = cheaper
P/E (12 months)22.2× · Pricier than median
P/B1.72× · Pricier than median
P/S (12 months)8.22× · Priciest 25%
Price / free cash flow (fiscal year)19.4× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Xuchang Ketop Testing Research Ins Fair Value". https://www.fairvalue-calculator.com/stock/003008
Frequently asked questions
Is Xuchang Ketop Testing Research Ins (003008) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥15.53 versus a price of ¥17.56, about 12% lower (overvalued).
What is the fair value of 003008?
Our model-based fair value for Xuchang Ketop Testing Research Ins is ¥15.53 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥17.56.
What is the quality score of 003008?
Xuchang Ketop Testing Research Ins has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xuchang Ketop Testing Research Ins (003008)?
Our model-based price target is the fair value of ¥15.53 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario ¥10.58, optimistic scenario ¥20.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Xuchang Ketop Testing Research Ins stock forecast for 2026?
Our models put fair value at ¥15.53, about 12% lower versus a price of ¥17.56 (overvalued). Cautious scenario ¥10.58, optimistic scenario ¥20.93. The calculation is refreshed regularly with new filings.
What is the revenue of Xuchang Ketop Testing Research Ins (003008)?
Xuchang Ketop Testing Research Ins reported trailing-twelve-month revenue of about 222M CNY (latest available figure, as of Nov 6, 2026).
Does Xuchang Ketop Testing Research Ins pay a dividend?
Xuchang Ketop Testing Research Ins currently shows a dividend yield of 2.85% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Xuchang Ketop Testing Research Ins (003008) and when is the ex-dividend date?
Xuchang Ketop Testing Research Ins pays a dividend of ¥0.5 per share a year, a dividend yield of 2.8%. The last ex-dividend date was Sep 3, 2026. A dividend has been paid every year since at least 2021. The payout ratio is 63.3% of earnings. Free cash flow covers the dividend 1.80 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Xuchang Ketop Testing Research Ins (003008)?
For today's price to be fair in a discounted-cash-flow model, Xuchang Ketop Testing Research Ins would have to grow free cash flow by +5.0 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.1 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 003008 use?
Our models discount Xuchang Ketop Testing Research Ins at 11.9 %: a base by market capitalisation (micro), damped by beta 0.43, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Xuchang Ketop Testing Research Ins that is +5.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Xuchang Ketop Testing Research Ins (003008) delivered so far?
Over the past 5 years revenue at Xuchang Ketop Testing Research Ins grew +7.1 % a year. The price currently implies free-cash-flow growth of +5.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Xuchang Ketop Testing Research Ins (003008) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into Xuchang Ketop Testing Research Ins (+5.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Xuchang Ketop Testing Research Ins (003008)?
The free-cash-flow yield on the price is 5.15 %: that much free cash flow Xuchang Ketop Testing Research Ins produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Xuchang Ketop Testing Research Ins (003008)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xuchang Ketop Testing Research Ins it is ¥15.53 per share (as of Nov 6, 2026), against a price of ¥17.56. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Xuchang Ketop Testing Research Ins stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 003008 trades above its calculated fair value: price ¥17.56, fair value ¥15.53, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 003008?
No. The price is what the market pays today (¥17.56); the fair value is what the company's own numbers justify (¥15.53). For Xuchang Ketop Testing Research Ins the two are ¥2.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xuchang Ketop Testing Research Ins worth?
The market values Xuchang Ketop Testing Research Ins at about 1.8B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥17.56; our models calculate a fair value of ¥15.53 per share.
What do the bullish and bearish scenarios say about 003008?
Our models span a range for Xuchang Ketop Testing Research Ins: cautious scenario ¥10.58, base ¥15.53, optimistic ¥20.93 per share (as of Nov 6, 2026, price ¥17.56). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 003008?
Xuchang Ketop Testing Research Ins trades at a price-to-earnings ratio of 22.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥15.53 is built from several models across several years. Other multiples: P/B 1.7, P/S 8.2, EV/EBITDA 12.4.
How solid is the balance sheet of Xuchang Ketop Testing Research Ins (003008)?
Balance-sheet figures for Xuchang Ketop Testing Research Ins (as of Nov 6, 2026): return on equity 7.9%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 003008 from its 52-week high?
Xuchang Ketop Testing Research Ins trades at ¥17.56, about 27% below its 52-week high of ¥24.19 and 10% above the low of ¥16.00 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ¥15.53 is for.
Which stocks are comparable to Xuchang Ketop Testing Research Ins?
From the same area (Industrials) we also value Cintas Corporation, Thomson Reuters Corporation, Copart, Inc, Global Payments Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xuchang Ketop Testing Research Ins stock attractive at the current price?
The data as of Nov 6, 2026: price ¥17.56, calculated fair value ¥15.53 (−12%), Quality Score 74/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 003008 calculated?
We run Xuchang Ketop Testing Research Ins through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥15.53 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Xuchang Ketop Testing Research Ins itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xuchang Ketop Testing Research Ins (003008)?
The closing price on Nov 9, 2026 was ¥17.56. Our model-based fair value is ¥15.53, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xuchang Ketop Testing Research Ins right now?
A fairly wide model range (¥10.58 to ¥20.93) leaves room in how you read the outcome. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Xuchang Ketop Testing Research Ins
How large is the market capitalisation of Xuchang Ketop Testing Research Ins (003008)?
The market capitalisation of Xuchang Ketop Testing Research Ins is 1.8B CNY (≈ $273M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Xuchang Ketop Testing Research Ins (003008)?
The price-to-sales ratio of Xuchang Ketop Testing Research Ins is 8.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Xuchang Ketop Testing Research Ins (003008)?
Earnings per share at Xuchang Ketop Testing Research Ins are ¥0.7900 (price ÷ EPS = P/E 22.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Xuchang Ketop Testing Research Ins (003008)?
The dividend yield of Xuchang Ketop Testing Research Ins is 2.8% (payout 63.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Xuchang Ketop Testing Research Ins (003008)?
The net margin of Xuchang Ketop Testing Research Ins is 36.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Xuchang Ketop Testing Research Ins (003008)?
The return on equity (ROE) of Xuchang Ketop Testing Research Ins is 7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xuchang Ketop Testing Research Ins (003008)?
On an EBIT basis the return on assets of Xuchang Ketop Testing Research Ins is 7.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xuchang Ketop Testing Research Ins (003008)?
The operating margin of Xuchang Ketop Testing Research Ins is 35.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xuchang Ketop Testing Research Ins (003008)?
Revenue at Xuchang Ketop Testing Research Ins is growing +8.1% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Xuchang Ketop Testing Research Ins (003008)?
Earnings per share at Xuchang Ketop Testing Research Ins are growing +13.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Xuchang Ketop Testing Research Ins (003008) hold?
Xuchang Ketop Testing Research Ins holds more cash than debt, 93.4M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Xuchang Ketop Testing Research Ins in the live analysis
One click puts Xuchang Ketop Testing Research Ins on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026